CAC
STOK icon

Cowen and Company’s Stoke Therapeutics STOK Stock Holding History

Cowen and Company’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-3,244,498
Closed -$39.9M – 276
2024
Q3 		$39.9M Sell
3,244,498
-121,246
-4% -$1.72M 1.34% 14
2024
Q2 		$45.5M Hold
3,365,744
– – 1.25% 13
2024
Q1 		$45.4M Sell
3,365,744
-355,915
-10% -$2.16M 1.76% 8
2023
Q4 		$19.6M Hold
3,721,659
– – 1.28% 22
2023
Q3 		$14.7M Hold
3,721,659
– – 1.03% 25
2023
Q2 		$39.6M Buy
3,721,659
+442,517
+13% +$4.71M 3.28% 7
2023
Q1 		$27.3M Buy
3,279,142
+2,531,065
+338% +$22.8M 3.21% 5
2022
Q4 		$6.9M Sell
748,077
-21,092
-3% -$219K 0.72% 27
2022
Q3 		$9.88M Sell
769,169
-740,451
-49% -$11.8M 0.94% 26
2022
Q2 		$19.9M Buy
1,509,620
+89,090
+6% +$1.35M 1.93% 14
2022
Q1 		$29.9M Buy
1,420,530
+1,125,105
+381% +$22.5M 2.88% 9
2021
Q4 		$6.83M Buy
295,425
+259,526
+723% +$6.19M 0.62% 32
2021
Q3 		$913K Buy
+35,899
New +$1M 0.04% 153

Other funds holding STOK

ST
Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Cowen and Company's STOK Position: Q4 2024 in Review

Cowen and Company sold out of Stoke Therapeutics (STOK) in Q4 2024, closing a stake of 3,244,498 shares — an estimated $39.9M sold.

Cowen and Company first reported a position in STOK in Q3 2021 and held it in 13 quarters. The position peaked at $45.5M in Q2 2024. 130 funds tracked by Wall St. Rank hold STOK as of Q4 2024.

  • Cowen and Company reported no remaining Stoke Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Cowen and Company sold 3,244,498 Stoke Therapeutics shares in Q4 2024, an estimated $39.9M.
  • Cowen and Company first reported a position in Stoke Therapeutics in Q3 2021 and held it in 13 quarters.
  • Cowen and Company's Stoke Therapeutics position peaked at $45.5M in Q2 2024.
  • 130 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q4 2024.

Based on Cowen and Company's 13F filing for Q4 2024.